ERBB2 and breast cancer: We focused on T-DXd for the synthetic lethal screening because recent clinical trial data indicated that T-DXd is associated with improved overall survival and progression-free survival compared to T-DM1 in patients with HER2+ metastatic BC [38]; T-DXd is also now a standard second-line therapy in these patients.